Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
Hepatitis C
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
A phase 3 Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of the combined single dose of Dactavira Plus (EPGCG, Sofosbuvir , Daclatasvir \& Ribavirin) versus Sofosbuvir + Daclatasvir + Ribavirin (Part A) and a…
- Trial name
- NCT03186313
- Testing
- Dactavira Plus, Sofosbuvir + Daclatasvir + Ribavirin, Dactavira
- Where
- Egypt
- Volunteers
- 72 people
- Sponsor
- Egyptian Liver Hospital
Chronic Hepatitis C
Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3.
- Trial name
- NCT01151397
- Testing
- Peg + Vitamin D + Ribavirin, Peg + Ribavirin
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Ziv Hospital
Porphyria Cutanea Tarda, Hepatitis C
Harvoni Treatment Porphyria Cutanea Tarda
In the medical literature there case reports that Harvoni improves symptoms in patients with PCT. However, this has never been systematically tested.
- Trial name
- NCT03118674
- Testing
- Harvoni
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Wake Forest University Health Sciences
Hepatitis C, Chronic
SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C
Phase II: Exploring the efficacy and safety of different doses of SH229 tablets combined with fixed-dose Daclatasvi dihydrochloride (DCV) tablets in the treatment of adult patients with chronic hepatitis C for 12 weeks, providing…
- Trial name
- NCT04070235
- Testing
- SH229 tablets, Daclatasvir dihydrochloride
- Where
- China
- Volunteers
- 440 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Chronic Hepatitis C
Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C
The objective of this pilot project is to investigate the prognostic criteria for sensitivity of Chronic Hepatitis C (CHC) Genotype 1, patients to IFNa treatment.
- Trial name
- NCT00876174
- Testing
- Blood sampling of peripheral blood mononuclear cells, Blood draw, 20ml peripheral blood mononuclear cells
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Nebraska
Hepatitis C, Depression
Paroxetine for the Treatment of Interferon Related Side Effects for Hepatitis C
A.OVERVIEW This is a 26 week study examining the ability of paroxetine (Paxil) to prevent the development of depression and neurotoxicity in patients receiving either 3 million units of subcutaneous IFN(interferon-alpha-2b) 3…
- Conditions
- Hepatitis C, Depression, Interferon-alpha Associated Side Effects
- Trial name
- NCT00209118
- Testing
- paroxetine
- Volunteers
- 60 people
- Sponsor
- Emory University
Liver Disease Chronic, HEPATITIS C VIRUS CHRONIC INFECTION
Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).
The purpose of this clinical trial is to evaluate whether a nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein improves biochemical and molecular markers, as well as clinical outcomes, in…
- Trial name
- RESQUETI (NCT07487623)
- Testing
- resveratrol, quercetin, taurine, whey protein, and inulin, whey protein
- Where
- 2 sites in Mexico
- Volunteers
- 26 people
- Sponsor
- University of Guadalajara
Hepatitis C, Chronic
Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan
To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan
- Trial name
- NCT03200379
- Testing
- directly acting antivirals (DAAs)
- Where
- Taiwan
- Volunteers
- 150,000 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis C
Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects
The main purpose of this study is to determine the safety and tolerability of multiple dosing of miravirsen in subjects infected with chronic hepatitis C.
- Trial name
- NCT01200420
- Testing
- miravirsen, saline
- Where
- 7 sites in United States, Germany and 4 more
- Volunteers
- 38 people
- Sponsor
- Santaris Pharma A/S
Hepatitis C, Chronic
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the safety and efficacy of co-administration of ABT-450 (also known as paritaprevir) with ritonavir (ABT-450/r) and ABT-267 (also known as ombitasvir) in adults with chronic hepatitis C…
- Trial name
- PEARL-I (NCT01685203)
- Testing
- ABT-450/r, ABT-267, Ribavirin (RBV)
- Volunteers
- 316 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Hepatitis C Infection
Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults
The study will evaluate the safety and pharmacokinetics of single doses of VBY-376 in healthy subjects.
- Trial name
- NCT00557583
- Testing
- VBY 376
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Virobay Inc.
Hepatitis C
Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin
Genotype 1 hepatitis C virus (HCV) patients who did not respond (did not lose virus during treatment) or relapsed (virus went away on treatment but came back after treatment was stopped) after treatment with at least twelve weeks…
- Trial name
- NCT00207402
- Testing
- rosiglitazone
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Brooke Army Medical Center
Hepatitis C, Chronic
HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
This study evaluated the safety and efficacy of peginterferon alfa-2a monotherapy in participants with Chronic Hepatitis C (CHC) who have End-Stage Renal Disease (ESRD) and were undergoing hemodialysis.
- Trial name
- NCT02806505
- Testing
- Peginterferon alfa-2a
- Where
- 22 sites in Austria, Brazil and 6 more
- Volunteers
- 81 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C, Fibrosis
Combination Drug Therapy for Patients With Hepatitis C
Hepatitis C is a major cause of liver disease in the United States and leads to cirrhosis of the liver in approximately one-third of patients some of whom will ultimately suffer from liver failure or liver cancer.
- Conditions
- Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
- Trial name
- NCT00001729
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis C
"Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt
The primary purpose of the ANRS 12332 HepNile study cohort is to assess in "Real-Life" condition the efficacy and the safety profile of new Direct Acting Antivirals (DAAs) introduced in the Egyptian National Treatment Programme…
- Trial name
- HepNile (NCT03510637)
- Where
- 3 sites in Egypt
- Volunteers
- 7,500 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C
Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)
This is a randomized, multi-site, open-label trial of a fixed-dose combination of Grazoprevir (MK-5172) and Elbasvir (MK-8742) versus Boceprevir (BOC) / Pegylated Interferon (P) and Ribavirin (R) in treatment-naive and prior…
- Trial name
- NCT02204475
- Testing
- Grazoprevir/Elbasvir, Boceprevir, PegIntron
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C, HCV
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of ABT-493/ABT-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or renal transplant with chronic hepatitis C…
- Conditions
- Chronic Hepatitis C, HCV, Hepatitis C Virus
- Trial name
- NCT02692703
- Testing
- glecaprevir/pibrentasvir
- Volunteers
- 100 people
- Sponsor
- AbbVie
Hepatitis C
Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)
To determine the relapse rate at 24 weeks follow up in Hepatitis C Virus Genotype 1 Low Viral Load (HCV LVL G1) patients treated for 24 weeks with Peg Intron and Rebetol who are Hepatitis C Virus-Ribonucleic Acid (HCV-RNA)…
- Trial name
- NCT00709228
- Testing
- PegIntron, Rebetol
- Volunteers
- 496 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C, Hemophilia
Viral Kinetics in HCV Clearance in Subjects With Hemophilia
This study will examine viral dynamic responses in subjects with chronic hepatitis C and hemophilia when treated with pegylated interferon + ribavirin and telaprevir.
- Trial name
- HCV/Hemophil (NCT01704521)
- Testing
- PegInterferon, Ribavirin, Telaprevir
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Kenneth Sherman
Hepatitis C, Chronic
Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus
The primary objective is to determine the safety of sub-cutaneous (SC) injections of TG4040 in non-cirrhotic, treatment-naïve patients chronically infected with HCV (genotype 1).
- Trial name
- NCT00529321
- Testing
- MVA-HCV (Immunotherapy)
- Where
- 6 sites in France
- Volunteers
- 42 people
- Sponsor
- Transgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.